Navigation Links
Cord Blood America Management Team to Appear on National VoiceAmerica Radio Network
Date:10/21/2010

LAS VEGAS, Oct. 21 /PRNewswire/ -- Cord Blood America, Inc. (http://www.cordblood-america.com) (OTC Bulletin Board: CBAI), the umbilical cord blood stem cell preservation company focused on bringing the life-saving potential of stem cells to families nationwide and internationally, is pleased to announce that Chairman, CEO and co-founder Matthew Schissler and Dr. Geoffrey O'Neill, Vice President, Operations, will appear for one hour live on "Go Rogue & Get Rich" on The VoiceAmerica Radio Network.

Both Mr. Schissler and Dr. O'Neill will first describe the cord blood collection, process and storage procedure, and take questions about cord blood stem cells, including processing and storage, from the audience during the live international radio show at 2 p.m. Pacific, 5 p.m. Eastern on Monday, October 25 on the VoiceAmerica.com Business Channel (Go Rogue & Get Rich!) http://www.voiceamerica.com.

"We are honored that Kevin asked us to be on the show. We recognize his show is geared towards building businesses. Any opportunity to preach the cord blood gospel is welcome by CBAI," Mr. Schissler said.

Kevin Lehmann, who hosts the program, is well known for his business acumen and advocacy for entrepreneurship and free enterprise. He successfully launched the largest lead generation and sales and marketing training company in Network Marketing history, helping to revolutionize the sector with a high-tech/high-touch philosophy.

Mr. Schissler co-founded Cord Blood America, Inc. in 2003 with the vision of bringing the life-saving potential of stem cells to families in the U.S. and worldwide. He has positioned the company to focus on strategic organic growth, accretive acquisitions and diversifying into new, undiscovered stem cell processing and storage opportunities.

Dr. O'Neill, who has 25 years experience in the stem cell industry, has published 78 papers on the sector. He was the recipient of the prestigious Jean Julliard Prize for Research from the International Society of Blood Transfusion and the International Society of Hematology.

"We are looking forward to this opportunity to tell a national audience about the accomplishments and future plans for Cord Blood America, which now has an international presence, with affiliations in China, South America and throughout Europe," Mr. Schissler said.

About Cord Blood AmericaCord Blood America is the parent company of CorCell, which facilitates umbilical cord blood stem cell preservation for expectant parents and their children. Its mission is to be the most respected stem cell preservation company in the industry. Collected through a safe and non-invasive process, cord blood stem cells offer a powerful and potentially life-saving resource for treating a growing number of ailments, including cancer, leukemia, blood, and immune disorders. To find out more about Cord Blood America, Inc., visit our website at http://www.corcell.com/. For investor information, visit http://www.cordblood-america.com/.CONTACT:Paul KnopickE & E Communications949/707-5365pknopick@eandecommunications.com
'/>"/>

SOURCE Cord Blood America, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related biology technology :

1. FDA Grants Full Approval of PROCLEIX(R) ULTRIO(R) Blood Screening Assay
2. Biotest Diagnostics Receives FDA Clearance for Full Line of Traditional Blood Bank Reagents
3. Limbs saved by menstrual blood stem cells
4. Sanofi Aventis : New Study Results Support the "Basal Plus" Strategy With LANTUS(R) and APIDRA(R) to Improve Blood Sugar Control in Patients With Type 2 Diabetes
5. Human Trial Results Show Plant Extract Tops Drug at Regulating Blood Sugar Levels; Huge Market Seen for Newly Developed Food Additive Emulin™
6. No Blood Needed Thanks to Innovative Medical Technology
7. The Modern DeBakey VAD™ To Be Introduced For the First Time in the U.S. : HeartAssist 5™ Pediatric VAD Features Industry Exclusive Direct Blood Flow Measurement System
8. Cepheid Receives FDA Clearance for First On-Demand Diagnostic Test for Life-Threatening MRSA and Staphylococcus aureus From Patient Positive Blood Cultures
9. CORD:USE Cord Blood Bank is Proud to Announce that Cord Blood Pioneer and Leading Transplanter Dr. Eliane Gluckman has Joined its Team
10. American Red Cross Expands Agreement for Strategic Blood Management(TM) Services from Strategic Healthcare Group LLC
11. China Biologic Products Enters Into Agreement to Acquire 35% Interest in Xian Huitian Blood Products Co., Ltd. and Introduces Preliminary Guidance for 2009
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/24/2017)... On Thursday, March 23, 2017, ... down 0.07%; the Dow Jones Industrial Average edged 0.02% ... closed at 2,345.96, marginally dropping 0.11%. US markets saw ... 4 sectors finished in red, and 1 sector ended ... reports coverage on the following Biotechnology equities: BioDelivery Sciences ...
(Date:3/23/2017)... (PRWEB) , ... March 23, 2017 , ... ... viscoelastic material that exhibits both viscous and elastic characteristics when deformed, which is ... polymer exhibits properties to gently absorb compressive forces and return to its natural ...
(Date:3/23/2017)... March 23, 2017  Northwest Biotherapeutics (OTCQB: NWBO) ... immune therapies for solid tumor cancers, today announced ... financing it announced last Friday, March 17, 2017. ... institutional investors securities totaling 28,843,692 shares, comprised of ... 10,000,000 shares of Class C Warrants pre-funded at ...
(Date:3/23/2017)... MENLO PARK, Calif., March 23, 2017  BioPharmX ... developing products for the dermatology market, today reported ... Jan. 31, 2017, and will provide an update ... from the year. "We are pleased ... productive year for BioPharmX," said President Anja Krammer. ...
Breaking Biology Technology:
(Date:3/2/2017)... -- Summary This report provides all the information ... and activities since 2010. ... Read the full report: http://www.reportlinker.com/p03605615-summary/view-report.html ... provides an in-depth insight into the partnering activity of one ... demand company reports are prepared upon purchase to ensure inclusion ...
(Date:3/2/2017)... Australian stem cell and regenerative medicine company, ... an agreement with the Monash Lung Biology Network, a ... and Department of Pharmacology at Monash University, ... to support the use of Cymerus™ mesenchymal stem cells ... Asthma is a chronic, long term lung condition recognised ...
(Date:2/28/2017)... , February 28, 2017 News solutions ... ... Amsterdam from 14 to 16 March, Materna will ... and show how seamless travel is a real benefit for passengers. ... added biometrics to their passenger touch point solutions to take passengers ...
Breaking Biology News(10 mins):